| Literature DB >> 29661204 |
Rimantas Bausys1,2, Augustinas Bausys3,4, Indre Vysniauskaite5, Kazimieras Maneikis2, Eugenijus Stratilatovas1,2, Kestutis Strupas2,6.
Abstract
BACKGROUND: The proportion of early gastric cancer stages is increasing, as is the incidence of gastric cancer among the elderly population. Therefore, this study was designed to analyze surgical treatment outcomes of T1-T2 gastric cancer in elderly patients.Entities:
Keywords: Early invasion; Elderly patients; Gastric cancer; T1; T2
Mesh:
Year: 2018 PMID: 29661204 PMCID: PMC5902993 DOI: 10.1186/s12957-018-1388-4
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Comparison of patient characteristics
| Group NE (< 70 years) | Group E (≥ 70 years) | |||||
|---|---|---|---|---|---|---|
|
| % |
| % | |||
| Sex | Male | 150 | 56.2 | 111 | 58.4 | 0.701 |
| Female | 117 | 43.8 | 79 | 41.6 | ||
| Age | 58.18 ± 8.86 | 76.43 ± 4.35 | 0.001 | |||
| BMI | 26.2 ± 5.72 | 25.9 ± 4.90 | 0.700 | |||
| ASA score | 1–2 | 177 | 68.3 | 71 | 38.6 | 0.001 |
| 3–4 | 82 | 31.7 | 113 | 61.4 | ||
| Tumor localization (third) | Upper 1/3 | 51 | 19.1 | 26 | 16.8 | 0.147 |
| Middle 1/3 | 119 | 44.6 | 80 | 42.1 | ||
| Lower 1/3 | 97 | 36.3 | 84 | 44.2 | ||
| Gastrectomy | Total | 83 | 31.1 | 47 | 24.7 | 0.143 |
| Subtotal | 184 | 68.9 | 143 | 75.3 | ||
| Lymphanodectomy | D1 | 13 | 5.0 | 18 | 9.8 | 0.059 |
| D2 | 246 | 95.0 | 165 | 90.2 | ||
| Multivisceral surgery | Yes | 19 | 7.3 | 15 | 8.2 | 0.721 |
| No | 241 | 92.7 | 168 | 91.8 | ||
| Tumor invasion | T1a | 64 | 24.0 | 35 | 18.4 | 0.217 |
| T1b | 63 | 23.6 | 56 | 29.5 | ||
| T2 | 140 | 52.4 | 99 | 52.1 | ||
| Lymph node metastasis | Yes | 101 | 37.8 | 74 | 38,9 | 0.845 |
| No | 166 | 62.2 | 116 | 61,1 | ||
| N categories | N0 | 166 | 62.2 | 116 | 61.1 | 0.778 |
| N1 | 65 | 24.3 | 49 | 25.8 | ||
| N2 | 19 | 7.1 | 17 | 8.9 | ||
| N3 | 17 | 6.3 | 8 | 4.3 | ||
| Distant metastasis | Yes | 5 | 1.9 | 3 | 1.6 | 0.999 |
| No | 262 | 98.1 | 187 | 98.4 | ||
| Lauren classification | Diffuse | 112 | 42.3 | 17 | 21.8 | 0.001 |
| Mix | 31 | 11.7 | 6 | 8.9 | ||
| Intestinal | 121 | 45.8 | 63 | 69.3 | ||
| Tumor differentiation grade | G1 | 27 | 10.1 | 25 | 13.2 | 0.001 |
| G2 | 69 | 25.8 | 84 | 44.2 | ||
| G3 | 171 | 64.0 | 81 | 42.6 | ||
| Tumor size | < 2 cm | 88 | 34.2 | 56 | 30.6 | 0.471 |
| ≥ 2 cm | 169 | 65.8 | 127 | 69.4 | ||
Short-term surgical outcomes of NE and E patients who underwent gastrectomy for pT1-T2 gastric cancer
| Factors | Group NE (< 70 years) | Group E (≥ 70 years) | ||
|---|---|---|---|---|
| Operation time: min (mean ± SD; min-max) | 146.9 ± 41.58 | 143.72 ± 44.53 | 0.432 | |
| Blood loss: ml (mean ± SD; min-max) | 171.82 ± 137.11 | 169.50 ± 136.50 | 0.879 | |
| ICU stay: days (mean ± SD; min-max) | 1.24 ± 1.24 | 2.23 ± 6.30 | 0.014 | |
| Postoperative hospital stay: days (mean ± SD; min-max) | 13.07 ± 5.86 | 14.05 ± 8.24 | 0.145 | |
| Dissected lymph nodes (mean ± SD) | 22.18 ± 10.28 | 19.50 ± 9.43 | 0.005 | |
| Curability | R0 | 259 (97.0%) | 182 (95.8%) | 0.484 |
| R1,2 | 8 (3.0%) | 8 (4.2%) | ||
| Postoperative complications: | 55/267 (20.5%) | 51/190 (26.8%) | 0.144 | |
| Surgical complications | 29/267 (10.8%) | 20/190 (10.5%) | 0.909 | |
| Anastomotic leakage | 2/267 (0.7%) | 5/190 (2.6%) | 0.133 | |
| Postoperative bleeding | 6/267 (2.2%) | 4/190 (2.1%) | 0.999 | |
| Peritonitis/ intraabdominal abscess | 5/267 (1.8%) | 3/190 (1.5%) | 0.999 | |
| Ileus | 3/267 (1.1%) | 0/190 (0.0%) | 0.269 | |
| Incisional surgical site infection and (or) eventration | 5/267 (1.8%) | 4/190 (2.1%) | 0.999 | |
| Postoperative pancreatitis | 5/267 (1.8%) | 2/190 (1.0%) | 0.704 | |
| Pancreatic/biliary/enterocutaneuos fistula | 3/267 (1.1%) | 2/190 (1.0%) | 0.999 | |
| Medical complications | 26/267 (9.7%) | 31/190 (16.3%) | 0.043 | |
| Cardiac insufficiency | 0/267 (0.0%) | 3/190 (1.5%) | 0.071 | |
| Pneumonia | 11/267 (4.1%) | 4/190 (2.1%) | 0.292 | |
| Sepsis | 0/267 (0.0%) | 3/190 (1.5%) | 0.071 | |
| PATE | 0/267 (0.0%) | 2/190 (1.0%) | 0.172 | |
| Other | 15/267 (5.6%) | 19/190 (10.0%) | 0.102 | |
| Clavien-Dindo | 1–2 | 39 (14.6%) | 30 (15.8%) | 0.195 |
| 3–4 | 16 (6.0%) | 10 (5.3%) | ||
| Postoperative mortality: | 0 (0.0%) | 11 (5.7%) | 0.001 | |
Univariate analysis of risk factors for postoperative complications in NE and E groups
| Group NE (< 70 years) | % | Group E (≥ 70 years) | % | ||||
|---|---|---|---|---|---|---|---|
| Sex | Male | 30/150 | 20.8 | 0.879 | 30/111 | 27.0 | 0.999 |
| Female | 25/117 | 21.4 | 21/79 | 26.6 | |||
| BMI | < 30 | 30/130 | 23.1 | 0.999 | 9/30 | 30.0 | 0.814 |
| ≥ 30 | 11/47 | 23.4 | 24/91 | 26.4 | |||
| ASA score | 1–2 | 33/177 | 18.6 | 0.144 | 11/71 | 15.5 | 0.006 |
| 3–4 | 22/82 | 26.8 | 39/113 | 34.5 | |||
| Gastrectomy | Total | 22/83 | 26.5 | 0.141 | 19/47 | 40.4 | 0.022 |
| Subtotal | 33/184 | 17.9 | 32/143 | 22.4 | |||
| Tumor localization (third) | Upper 1/3 | 15/51 | 29.4 | 0.077 | 11/26 | 42.3 | 0.157 |
| Middle 1/3 | 24/119 | 20.2 | 19/80 | 23.8 | |||
| Lower 1/3 | 16/97 | 16.5 | 21/84 | 25.0 | |||
| Multivisceral surgery | Yes | 2/19 | 10.5 | 0.381 | 8/15 | 53.3 | 0.031 |
| No | 53/241 | 22.0 | 42/168 | 25.0 | |||
| Lympha-nodectomy | D1 | 5/13 | 38.5 | 0.157 | 5/18 | 27.8 | 0.999 |
| D2 | 50/246 | 20.3 | 46/165 | 27.9 | |||
| Retrieved lymph nodes (LN) | ≤ 15 LN | 16/52 | 30.8 | 0.058 | 17/61 | 27.9 | 0.860 |
| > 15 LN | 39/211 | 18.5 | 33/127 | 26.0 |
Fig. 1Postoperative complications after surgery for different localizations gastric cancer. a Postoperative complications after surgery for different localization cancer in the entire study cohort. b Comparison of postoperative complications between non-elderly and elderly groups according to tumor localization
Fig. 2Overall survival after surgery for T1-T2 gastric cancer in elderly and non-elderly groups. Non-elderly (NE) patients have significantly higher 5-year overall survival rate after surgery for T1/T2 gastric cancer
Factors affecting overall survival in NE and E patient groups. Kaplan-Meier (univariate) and Cox regression (multivariate) analysis
| Group NE (< 70 years) | Group E (≥ 70 years) | ||||||
|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
| 5-year OS (%) | HR (95% CI); | 5-year OS (%) | HR (95% CI); | ||||
| Sex | Male | 66.0 | 0.263 | 5.24 (1.26–21.79); 0.023 | 46.8 | 0.094 | 0.64 (0.16–2.50); 0.528 |
| Female | 70.1 | 57.0 | |||||
| BMI | < 30 | 65.5 | 0.202 | 7.75 (1.37–43.72); 0.020 | 61.5 | 0.678 | 3.71 (0.69–19.69); 0.124 |
| ≥ 30 | 73.9 | 56.7 | |||||
| ASA score | 1–2 | 70.6 | 0.190 | 2.01 (0.59–6.80); 0.261 | 59.2 | 0.052 | 1.88 (0.53–6.70); 0.326 |
| 3–4 | 64.6 | 46.0 | |||||
| Lymphano-dectomy | D1 | 76.9 | 0.745 | 1.21 (0.74–1.86); 0.981 | 38.9 | 0.172 | 3.93 (0.37–40.80); 0.251 |
| D2 | 68.7 | 53.3 | |||||
| Retrieved lymph nodes | ≤ 15 | 73.1 | 0.310 | 1.15 (0.24–5.44); 0.854 | 45.9 | 0.443 | 2.89 (0.60–13.93); 0.186 |
| > 15 | 67.3 | 53.5 | |||||
| Gastrectomy | Total | 49.4 | 0.001 | 2.32 (0.59–9.14); 0.227 | 34.0 | 0.012 | 10.14 (2.15–47.77); 0.003 |
| Subtotal | 76.1 | 56.6 | |||||
| Multivisceral surgery | Yes | 47.4 | 0.006 | 1.93 (0.38–9.78); 0.425 | 53.6 | 0.019 | 22.83 (0.39–132.69); 0.131 |
| No | 70.5 | 33.3 | |||||
| Postoperative complications | Yes | 72.7 | 0.425 | 1.57 (0.38–6.43); 0.525 | 21.6 | 0.001 | 3.94 (1.05–14.82); 0.042 |
| No | 66.5 | 61.9 | |||||
| Tumor invasion | T1a | 89.1 | 0.001 | 5.81 (1.14–29.69); 0.034 | 65.7 | 0.010 | 4.29 (0.39–46.19); 0.229 |
| T1b | 85.7 | 62.5 | |||||
| T2 | 50.0 | 39.4 | |||||
| Lymph node metastasis | LNM+ | 80.7 | 0.001 | 2.02 (0.66–6.18); 0.215 | 36.5 | 0.001 | 0.54 (0.09–3.32); 0.512 |
| LNM- | 46.5 | 60.3 | |||||
| Distant metastasis | M1 | 0.0 | 0.001 | 4.30 (0.31–58.14); 0.271 | 51.9 | 0.001 | 2.20 (0.09–53.74); 0.628 |
| M0 | 69.1 | 0.0 | |||||
| Tumor localization (third) | Upper | 49.0 | 0.001 | 2.02 (0.36–11.21); 0.419 | 34.6 | 0.298 | 1.04 (0.29–3.74); 0.947 |
| Middle | 71.4 | 55.0 | |||||
| Lower | 73.2 | 52.4 | |||||
| Lauren classification (type) | Diffuse | 60.7 | 0.086 | 9.72 (1.73–54.53); 0.010 | 59.0 | 0.147 | 4.82 (0.99–17.41); 0.929 |
| Mix | 64.5 | 68.8 | |||||
| Intestinal | 74.4 | 44.4 | |||||
| Tumor differentiation grade | G1 | 81.5 | 0.037 | 2.21 (0.29–16.93); 0.443 | 68.0 | 0.074 | 3.78 (1.03–24.39); 0.910 |
| G2 | 76.8 | 42.9 | |||||
| G3 | 62.0 | 54.3 | |||||
| Ulceration | UL+ | 67.1 | 0.901 | 1.51 (0.55–4.15); 0.415 | 56.5 | 0.583 | 2.37 (0.66–8.51); 0.184 |
| UL- | 69.6 | 50.7 | |||||
| Lymphovascular invasion | LV+ | 45.8 | 0.001 | 2.00 (0.61–6.51); 0.250 | 42.9 | 0.005 | 2.50 (0.53–11.72); 0.245 |
| LV- | 79.1 | 60.9 | |||||
| Signet ring cell carcinoma | SRC+ | 67.7 | 0.601 | 2.49 (0.64–9.65); 0.186 | 71.4 | 0.354 | 3.92 (0.12–11.99); 0.433 |
| SRC- | 60.6 | 50.9 | |||||
| Tumor size | < 2 cm | 84.1 | 0.001 | 1.27 (0.37–4.31); 0.693 | 66.1 | 0.010 | 4.09 (0.80–20.95); 0.091 |
| ≥ 2 cm | 61.5 | 45.7 | |||||